Sionna advances dual combo to Phase 2a trial while cutting 46% staff
The company will initiate the AscenSION CF trial in Q1 2027 after post-hoc analyses. Cost-saving measures extend cash runway into late 2029.
Latest Sionna Therapeutics News & Updates
See the latest news and media coverage for Sionna. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing novel cystic fibrosis therapies
sionnatx.com- Headquarters
- Boston, United States
- Founded year
- 2019
- Company type
- Public company
- Number of employees
- 60–200
- Industry
- Pharmaceuticals
Last updated
Latest news about Sionna Therapeutics (Sionna)
In short: Sionna's shares crashed over 90% after its lead cystic fibrosis drug failed a Phase 2a trial, leading to a 46% staff reduction.
Company announcements
Sionna reported topline data from two cystic fibrosis trials
The trials evaluated NBD1 stabilizers as a potential treatment for cystic fibrosis, with full results available in a press release.
Sionna reports Phase 2a trial failed key endpoint and provides corporate update
The SION-719 add-on missed sweat chloride reduction, so it won't advance in that setting. SION-451 dual combos met safety and PK objectives, with SION-451+SION-2222 preferred, but next steps are under review. Cash was $268.3M.
Sionna reports Q1 2026 financial results
Net loss $26.8M, cash $289.9M funding into 2028. CF trial enrollment completed, topline data expected summer 2026.
Media coverage
Sionna Therapeutics, Inc.(NasdaqGM:SION) dropped from S&P Biotechnology Select Industry Index
Sionna Therapeutics, Inc. (NasdaqGM:SION) dropped from S&P Biotechnology Select Industry Index ...
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Alibaba Group Holding Limited of Class Action Lawsuit and Upcoming Deadlines - BABA
Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "Company") (NASDAQ: SION).
Sionna Therapeutics (SION) Approves 46% Job Cut. Can a New Trial Make its Cash More Productive?
Sionna Therapeutics, Inc. (NASDAQ:SION) announced on September 14 that its board approved an...
SION Maintained by Wedbush -- Price Target Raised to $6.00
Sionna Therapeutics Analyst Rating Update On October 11, 2023, Sionna Therapeutics (SION) received a...
Never miss news about Sionna
Track Sionna and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Sionna competitors & trending companies
Browse news for competitors to Sionna and other trending companies.